Patents by Inventor Carol Pachl
Carol Pachl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7138505Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host. The bacteriophage ?FVIII23D containing the 14.43 kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on Jul. 17, 1985 and given Accession No. 40190.Type: GrantFiled: August 13, 1990Date of Patent: November 21, 2006Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: George Kuo, Frank Masiarz, Martha Truett, Pablo Valenzuela, Mirella Ezban Rasmussen, Daniel Caput, Rae Lyn Burke, Carol Pachl
-
Publication number: 20020102562Abstract: The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characterization of the gB protein, including the identity of glycoprotein gp55, permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. This invention provides recombinant polypeptides and recombinant polynucleotides encoding these polypeptides wherein a neutralizing epitope of gB is localized within gp55.Type: ApplicationFiled: February 20, 2001Publication date: August 1, 2002Applicant: Pasteur Merieux Serums et Vaccines S.A.Inventors: Richard Spaete, Carol Pachl
-
Patent number: 6190860Abstract: The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characterization of the gB protein, including the identity of glycoprotein gp55, permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. This invention provides recombinant polypeptides and recombinant polynucleotides encoding these polypeptides wherein a neutralizing epitope of gB is localized within gp55.Type: GrantFiled: May 24, 1995Date of Patent: February 20, 2001Assignee: Chiron CorporationInventors: Richard R. Spaete, Carol A. Pachl
-
Patent number: 6100064Abstract: The present invention relates generally to modified secreted viral proteins, to the genes which express these proteins and to antibodies produced against such proteins, and to the use of these materials in diagnostic and vaccine applications. In particular, the present invention describes deletion of the transmembrane region only and retention of at least part of the cytoplasmic domain itself or fusion with at least part of an alternate cytoplasmic domain. The result will generally be the secretion of proteins which are normally membrane-bound (nonsecretory). This invention greatly increases the efficiency of secretion of the derivative protein. Specific viral proteins of interest include, but are not limited to, those from CMV, HSV, EBV, VZV, HCV, HIV, and influenza.Type: GrantFiled: July 29, 1994Date of Patent: August 8, 2000Assignee: Chiron CorporationInventors: Rae Lyn Burke, Karin Hartog, Carol Pachl
-
Patent number: 5834307Abstract: The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characterization of the gB protein, including the identity of glycoprotein gp55, permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. This invention provides recombinant polypeptides and recombinant polynucleotides encoding these polypeptides wherein a neutralizing epitope of gB is localized within gp55.Type: GrantFiled: May 24, 1995Date of Patent: November 10, 1998Assignee: Chiron CorporationInventors: Richard R. Spaete, Carol A. Pachl
-
Patent number: 5759814Abstract: The glycoprotein B ("gB") and analogs thereof are provided by recombinant DNA technology. Oligonucleotide sequences are provided coding the glycoprotein, its precursor and fragments thereof. Methods and compositions are disclosed for the production of the glycoprotein and analogous proteins as well as oligonucleotide sequences, which may be used for probes or other applications, and particularly may be used for vaccines.Type: GrantFiled: June 5, 1995Date of Patent: June 2, 1998Assignee: Chiron CorporationInventors: Rae L. Burke, Carol Pachl, Pablo D.T. Valenzuela
-
Patent number: 5750114Abstract: Vaccines and therapeutic compositions and methods for their production and use against Herpes Simplex Virus (HSV) are provided employing recombinant HSV glycoproteins B and D. The following E. coli HB101 strains were deposited at the A.T.C.C., where the plasmid indicates the plasmid employed to transform the strain; pHS203; pHS112; pHS114; pHS127A and pHS206 were deposited on Apr. 4, 1984, and assigned Accession Nos. 39649-39653, respectively; pYHS109 and pYHS118 were deposited on Jul. 11, 1984, and given Accession Nos. 39762 and 39763, respectively.Type: GrantFiled: May 30, 1995Date of Patent: May 12, 1998Assignee: Chiron CorporationInventors: Rae Lyn Burke, Carol Pachl, Pablo D. T. Valenzuela
-
Patent number: 5747039Abstract: Vaccines and therapeutic compositions and methods for their production and use against Herpes Simplex Virus (HSV) are provided employing recombinant HSV glycoproteins B and D.The following E. coli HB101 strains were deposited at the A.T.C.C., where the plasmid indicates the plasmid employed to transform the strain; pHS203; pHS112; pHS114; pHS127A and pHS206 were deposited on Apr. 4, 1984, and assigned Accession Nos. 39649-39653, respectively; pYHS109 and pYHS118 were deposited on Jul. 11, 1984, and given Accession Nos. 39762 and 39763, respectively.Type: GrantFiled: February 8, 1995Date of Patent: May 5, 1998Assignee: Chiron CorporationInventors: Rae Lyn Burke, Carol Pachl, Pablo D. T. Valenzuela
-
Patent number: 5648079Abstract: The glycoprotein B ("gB") and analogs thereof are provided by recombinant DNA technology. Oligonucleotide sequences are provided coding the glycoprotein, its precursor and fragments thereof. Methods and compositions are disclosed for the production of the glycoprotein and analogous proteins as well as oligonucleotide sequences, which may be used for probes or other applications, and particularly may be used for vaccines.Type: GrantFiled: December 8, 1994Date of Patent: July 15, 1997Assignee: Chiron CorporationInventors: Rae L. Burke, Carol Pachl, Pablo D. T. Valenzuela
-
Patent number: 5547834Abstract: The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characterization of the gB protein, including the identity of glycoprotein gp55, permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. This invention provides recombinant polypeptides and recombinant polynucleotides encoding these polypeptides wherein a neutralizing epitope of gB is localized within gp55.Type: GrantFiled: November 15, 1994Date of Patent: August 20, 1996Assignee: Chiron CorporationInventors: Richard R. Spaete, Carol A. Pachl
-
Patent number: 5244792Abstract: The glycoprotein B ("gB") and functional fragments thereof are provided by recombinant DNA technology. Oligonucleotide sequences are provided coding the glycoprotein, its precursor and fragments thereof. Methods and compositions are disclosed for the production of the glycoprotein and functional fragments thereof as well as oligonucleotide sequences, which may be used for probes or other applications, and particularly may be used for vaccines. The following E. coli HB101 strains were deposited at the A.T.C.C. on April 4, 1984, where the plasmid indicates the plasmid employed to transform the strain; pHS112; pHS114 (gB1 mammalian); pHS127A (gB1 yeast); pHS203; and pHS206 (gB2), and assigned Accession Nos. 39649-39653, respectively, where the nature of the plasmid is indicated in parentheses and the number refers back to the number employed in the Experimental section.Type: GrantFiled: September 20, 1990Date of Patent: September 14, 1993Assignee: Chiron CorporationInventors: Rae L. Burke, Carol Pachl, Pablo D. T. Valenzuela
-
Patent number: 5171568Abstract: Vaccines and therapeutic compositions and methods for their production and use against Herpes Simplex Virus (HSV) are provided employing recombinant HSV glycoproteins B and D.The following E. coli HB 101 strains were deposited at the A.T.C.C., where the plasmid indicates the plasmid employed to transform the strain; pH203; pHS112; pHS114; pHS127A and pHS206 were deposited on Apr. 4, 1984, and assigned Accession Nos. 39649-39653, respectively; pYHS109 and pYHS118 were deposited on Jul. 11, 1984, and given Accession Nos. 39762 and 39763, respectively.Type: GrantFiled: October 2, 1989Date of Patent: December 15, 1992Assignee: Chiron CorporationInventors: Rae L. Burke, Carol Pachl, Pablo D. T. Valenzuela
-
Patent number: 5045455Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host.The bacteriophage .lambda.FVIII23D containing the 14.43kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on July 17, 1985 and given Accession No. 40190.Type: GrantFiled: June 14, 1990Date of Patent: September 3, 1991Assignee: Chiron CorporationInventors: George Kuo, Frank Masiarz, Martha Truett, Pablo Valenzuela, Mirella E. Rasmussen, Jennifer M. Favaloro, Daniel Caput, Rae L. Burke, Carol Pachl